FTC Targets 300 ‘Junk Patents’ With Warning Letters, Including Ozempic – biolegacy

FTC Targets 300 ‘Junk Patents’ With Warning Letters, Including Ozempic

Post author:PacConAdmin
Post published:May 1, 2024
Post category:Uncategorized
Post comments:0 Comments

The Federal Trade Commission (FTC) continues slicing a machete through the patent thicket.
Source: Drug Industry Daily

Tags: aaps

Leave a Reply Cancel reply